Product category:
Chemicals and biochemicals
News Release from: Invitrogen | Subject: Division-arrested cell lines
Edited by the Laboratorytalk Editorial
Team on 16 July 2007
60 new division-arrested cell lines
Generated through a proprietary treatment of dividing cells, division arrested cells do not require lengthy and laborious cell culture procedures to prepare live cells for screening assays
Invitrogen launches the first suite of 60 division arrested cell lines for conveniently and cost-effectively screening a broad range of therapeutic targets Division arrested cells may be plated and assayed within 24 hours of thawing, and cell numbers increase only marginally after plating, thereby removing the variability caused by cell division during the course of an assay and providing more consistent results
This article was originally published on Laboratorytalk on 14 Sep 2005 at 8.00am (UK)
Related stories
Profiling service for immune response biomarkers
Provides researchers with a discovery method for rapid identification of biomarkers specific to disease states that result from altered immunoreactivity to self proteins
Cell lines keep on growing
Rapidly and reliably determine the intracellular status of key signal transduction pathways upon exposure to drug candidates or other stimuli
Division arrested cells show agonist-induced responses virtually indistinguishable from that of dividing cells, and exhibit no toxicity or apparent changes in signal transduction, ensuring researchers obtain the correct pharmacological profile.
The collection includes a broad range of cell lines developed for functional cell-based assays of G-protein coupled receptors, nuclear hormone receptors and hERG.
The cell lines are available in two configurations: 1x 384-well plate assay kits (including detection reagents) for small scale screening or evaluation purposes, and 10x384-well-plate kits for small to large scale screening.
Invitrogen acquired division arrest technology last year through the acquisition of Sentigen.
As part of the Sentigen transaction, Invitrogen owns the patent family which includes US Patent 7,045,281 and Australian Patent 2003270073.
Additional patent applications are currently pending in this family in the United States and a number of other countries.
• Invitrogen: contact details and other news
• Email this article to a colleague
• Register for the free Laboratorytalk email newsletter
• Laboratorytalk Home Page
Search the Pro-Talk network of sites
